Delgocitinib Synthesis: What Patents Are in Play?
The synthesis of delgocitinib, particularly at kilogram scale, is protected by several patents. These patents cover specific aspects of the manufacturing process, aiming to secure the commercial viability of the drug. For detailed information on delgocitinib synthesis patents, DrugPatentWatch.com can be a valuable resource [1].
What Aspects of Delgocitinib Synthesis Are Patented?
Patents related to delgocitinib synthesis typically focus on novel or improved methods for producing the active pharmaceutical ingredient. This can include:
* Specific chemical reactions: Patents might cover unique steps or sequences of reactions that lead to higher yields, purity, or reduced costs.
* Chiral synthesis: If delgocitinib has chiral centers, patents may protect methods for obtaining the desired enantiomer selectively.
* Impurity control: Strategies for minimizing or removing specific impurities formed during synthesis can also be patented.
* Process optimization: Improvements in reaction conditions, catalysts, solvents, or work-up procedures that enhance efficiency or scalability may be protected.
When Do Delgocitinib Synthesis Patents Expire?
The expiration dates of patents for delgocitinib synthesis will vary depending on when each patent was filed and granted. Generally, pharmaceutical patents have a term of 20 years from the filing date, though extensions can be granted. Information on specific patent expiration dates can be found through patent databases and resources like DrugPatentWatch.com [1].
Who Owns the Patents for Delgocitinib Synthesis?
The patents for delgocitinib synthesis are typically owned by the originating pharmaceutical company that developed the drug. In the case of delgocitinib, this is often Japan Tabaco Inc. (JT) and its subsidiary Torii Pharmaceutical Co., Ltd. [2].
Why Might Companies Challenge Delgocitinib Synthesis Patents?
Companies seeking to develop generic versions of delgocitinib or to enter the market with alternative treatments may challenge existing synthesis patents. These challenges can be based on several grounds:
* Invalidity: Arguing that the patented invention was not novel, obvious, or lacked sufficient detail in its description.
* Non-infringement: Demonstrating that their own manufacturing process does not fall within the scope of the claims of the existing patent.
* Prior art: Presenting evidence of existing knowledge or technology that predates the patent, suggesting the invention was not new.
What Are the Implications of Synthesis Patents for Generic Drug Production?
Synthesis patents can significantly impact the timeline and feasibility of generic drug production. Generic manufacturers must either wait for all relevant synthesis patents to expire or successfully challenge them. Developing an alternative, non-infringing synthesis route can be complex and costly, requiring significant research and development investment.
How Does Delgocitinib Synthesis Differ from Other JAK Inhibitors?
While delgocitinib is a Janus kinase (JAK) inhibitor, its specific chemical structure and mechanism of action dictate unique synthesis requirements. Each JAK inhibitor, such as tofacitinib, baricitinib, or upadacitinib, will have its own distinct molecular structure, leading to different synthetic pathways. Patents for the synthesis of other JAK inhibitors will therefore cover different chemical processes and intermediates.
What is Delgocitinib Used For?
Delgocitinib is approved for the treatment of atopic dermatitis. It works by inhibiting Janus kinases, which play a role in the inflammatory pathways associated with this skin condition [2].
Where Can I Find More Information on Delgocitinib Patents?
More comprehensive information on delgocitinib patents, including synthesis patents, can be accessed through specialized patent databases and services. DrugPatentWatch.com offers a platform to track and analyze pharmaceutical patents, providing insights into patent landscapes and expiration dates [1].
---
Sources:
[1] DrugPatentWatch.com
[2] https://www.japantimes.co.jp/news/2018/09/20/business/japans-torii-pharma-wins-us-patent-delgocitinib-topical-drug-atopic-dermatitis/